LA JOLLA, CA — Scientists from Scripps Research have developed a small molecule that blocks the activity of a protein linked to autoimmune diseases, including systemic lupus erythematosus (SLE) and Crohn’s disease. This protein, known as SLC15A4, has been considered largely “undruggable,” as most researchers had longed struggled to isolate...
treatment News
LOS ANGELES, Calif. – For the last three decades, breakthroughs have been sparse for soft tissue sarcomas, which are rare cancers that affect muscles, fat and other connective tissues. Today, a global team of researchers funded by a Stand Up To Cancer® (SU2C) grant announced clinical trial results that point...
Stockholm, Sweden – Dementia with Lewy bodies is a type of dementia that is similar to both Alzheimer’s disease and Parkinson’s disease but studies on long-term treatments are lacking. A new study from Karolinska Institutet in Sweden, published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, highlights the...
Patient-reported analyses demonstrated greater reduction in both cognitive and motor-related disease burden for INGREZZA compared with placebo Findings to be presented at the 2025 Advanced Therapeutics in Movement & Related Disorders (ATMRD) Congress SAN DIEGO, Calif. — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new patient-reported post-hoc data from the KINECT®-HD study highlighting significant reductions in...
JACKSONVILLE, Fla. — A new study published today in The Lancet showed results from the largest of its kind Phase III trial demonstrating a significant survival benefit for patients with oropharyngeal cancers who were treated with proton therapy compared to traditional radiation therapy. Led by researchers at the University of Texas MD Anderson...
Gov. M. Jodi Rell has signed legislation that will require health insurers to cover wound-care supplies for treatment of epidermolysis bullosa (EB), a rare genetic skin disease that causes blisters to develop easily from the slightest pressure. The bill takes effect Jan. 1, 2010. About 50 people in Connecticut have...
DUBLIN – Horizon Therapeutics plc (Nasdaq: HZNP) today announced new UPLIZNA (inebilizumab-cdon) data being presented at the American Academy of Neurology’s 73rd Annual Meeting being held virtually April 17-22, 2021 (AAN 2021), including new, end-of-study data from the open-label extension period of the pivotal N-MOmentum trial in patients with NMOSD. UPLIZNA is the first and...
SCOTTSDALE, Ariz. — MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report entitled “Thought Leader Insight & Analysis: Alzheimer’s Disease,” designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for diagnostics and treatments...
PLYMOUTH MEETING, PA — The National Comprehensive Cancer Network® (NCCN®) today announced publication of new NCCN Guidelines for Patients®: Small Bowel Adenocarcinoma. This free resource for people facing cancer and caregivers is focused on a rare cancer type that typically occurs in the small intestine, where routine screening is impossible,...
SPRING HOUSE, Pa. — Johnson & Johnson (NYSE: JNJ) announced today that 12 abstracts, including two oral presentations, highlighting the Company’s innovative autoantibody disease research and the potential of nipocalimab to provide long-term sustained disease control in the treatment of generalized myasthenia gravis (gMG), will be presented at the 2025...